---
layout: default
title: Pitolisant
description: "Pitolisant çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 3 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 129
evidence_level: L5
indication_count: 3
---

# Pitolisant

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>3</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Pitolisant è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Pitolisant å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Pitolisant ç‚ºé¸æ“‡æ€§çµ„ç¹”èƒº H3 å—é«”åå‘æ¿€å‹•åŠ‘ï¼ŒTxGNN é æ¸¬å°å¤±çœ åŠ ADHD æœ‰æ½›åœ¨ç™‚æ•ˆï¼Œå·²æœ‰æ–‡ç»æ”¯æŒå…¶ä¿ƒé†’åŠèªçŸ¥å¢å¼·ä½œç”¨ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥å“å­¸å | Pitolisant (å”¯é†’) |
| DrugBank ID | DB11642 |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | çŒç¡ç—‡ï¼ˆä¼´éš¨æˆ–æœªä¼´éš¨çŒå€’ï¼‰ã€é˜»å¡æ€§ç¡çœ å‘¼å¸ä¸­æ­¢å¼•èµ·çš„æ—¥é–“éåº¦å—œç¡ |
| TxGNN é æ¸¬æ–°é©æ‡‰ç—‡ | insomnia (disease)ã€attention deficit-hyperactivity disorderã€faciodigitogenital syndrome |
| å°ç£è¨±å¯è­‰æ•¸ | 4 å¼µ |
| æœ€é«˜è­‰æ“šç­‰ç´š | L3 (è§€å¯Ÿæ€§ç ”ç©¶/æ–‡ç»å›é¡§) |

## ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†

Pitolisant ä½œç‚º H3 å—é«”åå‘æ¿€å‹•åŠ‘ï¼Œå…¶é æ¸¬çš„æ–°é©æ‡‰ç—‡åœ¨æ©Ÿè½‰ä¸Šå…·æœ‰åˆç†æ€§ï¼š

1. **å¤±çœ  (Insomnia)**ï¼šH3 å—é«”é˜»æ–·å¯å¢åŠ è…¦å…§çµ„ç¹”èƒºé‡‹æ”¾ï¼Œä¿ƒé€²è¦ºé†’ã€‚é›–çœ‹ä¼¼çŸ›ç›¾ï¼Œä½†æ”¹å–„ç¡çœ -è¦ºé†’é€±æœŸèª¿æ§å¯èƒ½å°æŸäº›å¤±çœ é¡å‹æœ‰ç›Š
2. **æ³¨æ„åŠ›ä¸è¶³éå‹•ç—‡ (ADHD)**ï¼šçµ„ç¹”èƒºç³»çµ±åƒèˆ‡æ³¨æ„åŠ›åŠèªçŸ¥åŠŸèƒ½èª¿æ§ï¼ŒH3 å—é«”æ‹®æŠ—åŠ‘å¯å¢å¼·è¦ºé†’åŠæ³¨æ„åŠ›
3. **Aarskog ç—‡å€™ç¾¤**ï¼šé æ¸¬æ©Ÿè½‰ä¸æ˜ç¢ºï¼Œå¯èƒ½ç‚ºæ¨¡å‹å‡é™½æ€§

## è‡¨åºŠè©¦é©—è­‰æ“š

| é æ¸¬é©æ‡‰ç—‡ | è‡¨åºŠè©¦é©—æ•¸ | ä»£è¡¨æ€§è©¦é©— |
|------------|-----------|-----------|
| å¤±çœ  | 1 (é–“æ¥) | NCT02800083: Pitolisant æ²»ç™‚é…’ç²¾ä½¿ç”¨éšœç¤™ï¼ˆè©•ä¼°ç¡çœ ä½œç‚ºæ¬¡è¦æŒ‡æ¨™ï¼‰|
| ADHD | 0 | ç›´æ¥è©¦é©—ç„¡ï¼Œä½†æœ‰ç›¸é—œæ–‡ç»è¨è«– |

### ä¸»è¦è‡¨åºŠè©¦é©—

| è©¦é©— ID | æ¨™é¡Œ | Phase | ç‹€æ…‹ | èªªæ˜ |
|---------|------|-------|------|------|
| NCT02800083 | Pitolisant for Alcohol Use Disorder | Phase 2 | æ’¤å› | æ¬¡è¦æŒ‡æ¨™åŒ…å«ç¡çœ æ”¹å–„è©•ä¼° |

## æ–‡ç»è­‰æ“š

### å¤±çœ  (Insomnia)
**è­‰æ“šç­‰ç´šï¼šL3 (è§€å¯Ÿæ€§ç ”ç©¶/å›é¡§æ€§æ–‡ç»)**

| PMID | æ¨™é¡Œ | å¹´ä»½ | é‡é»ç™¼ç¾ |
|------|------|------|----------|
| 34225942 | Histamine receptors in health and disease | 2021 | ç¶œè¿° H3 å—é«”åœ¨ç¡çœ -è¦ºé†’èª¿æ§ä¸­çš„è§’è‰²ï¼ŒPitolisant ç‚ºæ²»ç™‚çŒç¡ç—‡çš„æ–°é¸é … |
| 36169322 | Real-life WAKE study in narcolepsy with pitolisant | 2022 | è§€å¯Ÿæ€§ç ”ç©¶é¡¯ç¤º Pitolisant å°æ—¢å¾€æ²»ç™‚ç„¡æ•ˆçš„çŒç¡ç—‡æ‚£è€…æœ‰æ•ˆï¼ŒæåŠå¤±çœ è©•ä¼° |
| 30214155 | Profile of pitolisant in narcolepsy management | 2018 | ç³»çµ±æ€§å›é¡§ Pitolisant çš„è—¥æ•ˆå­¸èˆ‡è—¥å‹•å­¸ç‰¹æ€§ |

### æ³¨æ„åŠ›ä¸è¶³éå‹•ç—‡ (ADHD)
**è­‰æ“šç­‰ç´šï¼šL3 (å‰è‡¨åºŠ/å›é¡§æ€§æ–‡ç»)**

| PMID | æ¨™é¡Œ | å¹´ä»½ | é‡é»ç™¼ç¾ |
|------|------|------|----------|
| 32882898 | Pitolisant and H3R antagonists: therapeutic potentials | 2020 | å›é¡§ H3R æ‹®æŠ—åŠ‘åœ¨ ADHD çš„æ½›åœ¨æ‡‰ç”¨ï¼ŒPitolisant å…·æœ‰èªçŸ¥å¢å¼·æ½›åŠ› |
| 34534876 | Drugs for epilepsy and excessive daytime sleepiness | 2021 | è¨è«– Pitolisant åœ¨åˆä½µ ADHD çš„ç™²ç™‡æ‚£è€…å¯èƒ½çš„è¼”åŠ©è§’è‰² |
| 27363923 | H3 receptor as target for cognitive symptoms | 2016 | æ¢è¨ H3R æ‹®æŠ—åŠ‘åœ¨ç¥ç¶“ç²¾ç¥ç–¾ç—…èªçŸ¥ç—‡ç‹€çš„æ²»ç™‚æ½›åŠ› |
| 21615387 | H3 receptor: from discovery to clinical trials | 2011 | æ­·å²å›é¡§åŠ Pitolisant è‡¨åºŠç™¼å±• |

## å°ç£ä¸Šå¸‚è³‡è¨Š

### ä¸Šå¸‚ç‹€æ…‹
å°ç£å·²æ ¸å‡†ä¸Šå¸‚ï¼Œå…±æœ‰ 4 å¼µè¨±å¯è­‰ï¼ˆ2 ç¨®åŠ‘é‡è¦æ ¼å„ 2 å¼µï¼‰ã€‚

### ä»£è¡¨æ€§ç”¢å“

| è¨±å¯è­‰å­—è™Ÿ | å•†å“å | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… | æ•ˆæœŸ |
|------------|--------|------|--------------|------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028103è™Ÿ | å”¯é†’è†œè¡£éŒ 4.5æ¯«å…‹ (Wakix) | è†œè¡£éŒ  | ä¿¡æ±ç”ŸæŠ€è‚¡ä»½æœ‰é™å…¬å¸ | 2026/07/13 |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028104è™Ÿ | å”¯é†’è†œè¡£éŒ 18æ¯«å…‹ (Wakix) | è†œè¡£éŒ  | ä¿¡æ±ç”ŸæŠ€è‚¡ä»½æœ‰é™å…¬å¸ | 2026/07/13 |

### æ ¸å‡†é©æ‡‰ç—‡
1. æ²»ç™‚ 6 æ­²ä»¥ä¸ŠçŒç¡ç—‡ï¼ˆä¼´éš¨æˆ–æœªä¼´éš¨çŒå€’ç¾è±¡ï¼‰
2. æ”¹å–„é˜»å¡æ€§ç¡çœ å‘¼å¸ä¸­æ­¢ (OSA) æˆäººç—…äººçš„è¦ºé†’ç‹€æ…‹ä¸¦æ¸›å°‘æ—¥é–“éåº¦å—œç¡ (EDS)

## å®‰å…¨æ€§è€ƒé‡

### è—¥ç‰©äº¤äº’ä½œç”¨

DDInter è³‡æ–™åº«é¡¯ç¤º Pitolisant èˆ‡å¤šç¨®è—¥ç‰©æœ‰äº¤äº’ä½œç”¨ï¼š

**åš´é‡äº¤äº’ä½œç”¨ (Major)**ï¼š
- Bupropionï¼šé™ä½ Pitolisant ä»£è¬ï¼Œå¢åŠ è¡€ä¸­æ¿ƒåº¦
- Dolasetronï¼šå¯èƒ½å»¶é•· QT é–“è·

**ä¸­åº¦äº¤äº’ä½œç”¨ (Moderate)**ï¼š
- H2 å—é«”é˜»æ–·åŠ‘ï¼šFamotidine, Cimetidine
- çš®è³ªé¡å›ºé†‡ï¼šHydrocortisone, Triamcinolone, Dexamethasone, Betamethasone, Budesonide
- å…¶ä»–ï¼šMetformin, Morphine, Clarithromycin, Levofloxacin
- ç€‰åŠ‘ï¼šBisacodyl, Polyethylene glycol

### æ³¨æ„äº‹é …
1. **QT å»¶é•·é¢¨éšª**ï¼šé¿å…èˆ‡å…¶ä»–å»¶é•· QT è—¥ç‰©ä½µç”¨
2. **CYP3A4 èª˜å°**ï¼šå¯èƒ½é™ä½ä½µç”¨è—¥ç‰©è¡€ä¸­æ¿ƒåº¦ï¼ˆå¦‚å£æœé¿å­•è—¥ï¼‰
3. **è‚è…åŠŸèƒ½ä¸å…¨**ï¼šä¸­é‡åº¦è‚åŠŸèƒ½ä¸å…¨éœ€æ¸›é‡
4. **æ‡·å­•/å“ºä¹³**ï¼šä¸å»ºè­°ä½¿ç”¨


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**èºé¬±ç—‡ (Bipolar Disorder)** ğŸŸ¡ Moderate
- Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive sympt...

**Psychotic Disorders** ğŸŸ¡ Moderate
- Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disord...

**Arrhythmias, Cardiac** ğŸŸ¡ Moderate
- Pitolisant prolongs the QT interval.  The use of pitolisant should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval.  The use of pitolisant should also be avoided in patients with a...

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- The pharmacokinetics of pitolisant in patients with end-stage renal disease (ESRD) (eGFR of <15 mL/minute/1.73 m2) is unknown.  Pitolisant is not recommended in patients with ESRD.  It is recommended to adjust the dosage of pitolisant when using this...

**Hepatic Insufficiency** ğŸŸ¢ Minor
- Pitolisant is contraindicated in patients with severe hepatic impairment.  Pitolisant is extensively metabolized by the liver.  Care should be exercised when using pitolisant in patients with moderate hepatic impairment.  It is recommended to monitor...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### é æ¸¬åƒ¹å€¼è©•ä¼°

| é æ¸¬é©æ‡‰ç—‡ | è­‰æ“šç­‰ç´š | æ–‡ç»æ”¯æŒ | è‡¨åºŠè©¦é©— | ç¸½è©• |
|------------|----------|----------|----------|------|
| å¤±çœ  | L3 | 8 ç¯‡ | 1 (é–“æ¥) | ä¸­åº¦æ”¯æŒ |
| ADHD | L3-L4 | 7 ç¯‡ | 0 | è¼•åº¦æ”¯æŒ |
| Aarskog ç—‡å€™ç¾¤ | L5 | 0 | 0 | ç„¡æ”¯æŒ |

### å»ºè­°
1. **ADHD**ï¼šåŸºæ–¼ H3 å—é«”åœ¨èªçŸ¥åŠŸèƒ½çš„è§’è‰²ï¼Œå€¼å¾—é€²ä¸€æ­¥æ¢ç´¢ï¼Œä½†ç›®å‰ç¼ºä¹ç›´æ¥è‡¨åºŠè©¦é©—
2. **å¤±çœ **ï¼šçœ‹ä¼¼çŸ›ç›¾ä½†æ”¹å–„ç¡çœ -è¦ºé†’é€±æœŸèª¿æ§å¯èƒ½å°æŸäº›ç¡çœ éšœç¤™æœ‰ç›Šï¼Œéœ€æ›´å¤šç ”ç©¶
3. Pitolisant ç›¸å°æ–°ç©ï¼ˆå°ç£ 2021 å¹´æ ¸å‡†ï¼‰ï¼Œè‡¨åºŠç¶“é©—ä»åœ¨ç´¯ç©ä¸­

---
*æœ¬ç­†è¨˜ç”± TwTxGNN ç³»çµ±è‡ªå‹•ç”¢ç”Ÿï¼Œåƒ…ä¾›ç ”ç©¶åƒè€ƒï¼Œä¸æ§‹æˆé†«ç™‚å»ºè­°ã€‚*
*ç”¢ç”Ÿæ—¥æœŸï¼š2026-02-11*


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Titanium Dioxide]({{ "/drugs/titanium_dioxide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Metoprolol]({{ "/drugs/metoprolol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Atezolizumab]({{ "/drugs/atezolizumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Etanercept]({{ "/drugs/etanercept/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Brivaracetam]({{ "/drugs/brivaracetam/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Pitolisantè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/pitolisant/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_pitolisant,
  title = {Pitolisantè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/pitolisant/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
